Copy
BC Members Meeting, PMPRB Call for Input, Petition Reminder, 6th Canadian Symposium on Hep C, and more.
View this email in your browser

AHC Update

September 2016

Welcome back to fall and routines and a renewed sense of getting on with it! Here is a round up of what has been happening over the summer and what is coming up this fall. 
Our 3rd Regional Hep C Advocacy Meeting will take place in Vancouver, BC on October 18-19, directly following a 1.5 day meeting of the Steering Committee. These promise to be a packed 3 days, so if you are a BC Member, Save the Date! Invitations went out in August and we look forward to productive sessions together.
The Patented Medicines Pricing Review Board (PMPRB) released a discussion paper on the modernization of their Pricing Guidelines. They have recognized that there are some problems with their math and the way that they price medicine in this country, which, you may recall, was the conclusion that we came to in our pricing statement as well.

They know they will receive lots of input from pharma companies and payers, but they want to make sure they really hear from patient groups as well. 

We are in the process of determining our AHC response to this paper currently, so stay tuned for information on a webinar to share our thoughts and discuss the issue, to help you formulate a response from your own organization if you choose to do so. The deadline for feedback is October 24 and we will likely plan our call for the last week of September.
We are just over 1/2 way there to the 500 signatures we need on our petition. Please sign on if you haven't yet!

CDEC's Updated Recommendations present Provincial/Territorial Advocacy Opportunities:


In June we reported that CADTH and the CDEC had updated their recommendations on the four curative HCV medicines that are currently approved in Canada for use on patients F0 and up, rather than F2 or higher - ie, fibrosis levels should not be an eligibility factor for treatment. (BTW, this is in line with AHC's Position paper released last November.)

As a follow up, we have sent some letters to the provinces and territories, (except BC, PEI and QC) letting them know about the update, as many provinces indicate that they use the CDEC recommendations to set their own formularies, and asking them when they plan to update their formularies from F2 to F0. We hope to be able to schedule meetings with some of them over the coming weeks to discuss this important policy change, which could really open up treatment eligibility in this country.

If you would like support in prepping a friendly MPP or MLA to raise this issue in your province, let us know, we would be happy to help. 
6th Canadian Symposium on HCV
Friday, March 3, 2017
The Fairmont Banff Springs Hotel

Visit canhepc.ca for more details.
Ontario Members: Please alert your MPP to BILL 216: The Greater Access to Hepatitis C Treatment Act.
AHC worked with MPP Sylvia Jones to bring forward this bill. It was tabled in provincial parliament just before the break, and calls upon Ontario to make HCV treatment accessible to patients, regardless of liver damage. 
View the bill here.

Have You Seen Our New Website?

We launched our new website in July, and if you haven't had a chance to see it yet, maybe today is the day. :) Let us know if there is something you would like to see more of on our site, or a resource that you would like to have to support your Hep C advocacy work.
Copyright © 2016 Action Hepatitis Canada, All rights reserved.


unsubscribe from this list    update subscription preferences 

Email Marketing Powered by Mailchimp